An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain,…
VERDICT
The label
Markup
read at $80.78
LivaNova PLC holds its Markup at $80.78.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-12
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 15 days
Price
$80.78
Valuation
23.83 trailing · 17.25 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.87
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$80.78
23.83 P/E · 17.25 fwd
Our fair value
$97.25
20% discount
Analyst target (avg)
$91.50
+13% to current
Target low $75.00Analyst target rangeTarget high $100.00
▲ current $80.78 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$80.78
you are here
Conservative
$77.26
-4%
Analyst avg
$91.50
+13%
Our fair value
$97.25
+20%
Analyst high
$100.00
+24%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
10.80%
Profit margin
12.81%
Debt to equity
26.56
Analyst consensus
Buy · 10 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 16.6% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 32.7% of assets, under the 49% limit.Pass
Revenue purityOnly 1.4% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Medical tech firm passes ethics but misses opportunity
A patient in Milan getting a nerve stimulator or a heart valve replaced relies on precise kit that must work first time. LivaNova makes those devices across Europe and the US, yet the numbers show only average returns on capital and thin margins for the sector. With revenue growing 14 percent and a forward multiple of 17.4 times, the business clears the ethical screen but does not clear the bar for a real edge over peers.
The 15 percent margin of safety to our fair value sits above the analyst median target of 84 dollars, yet return on equity at 10 percent and an unknown moat leave little room for error if growth slows. Unknown competitive protection plus modest profitability mean the shares are fairly valued at best, not mispriced.
Currency moves across its European markets and any slip in procedure volumes would hit earnings quickly. The rating stays at none because the setup offers safety without upside conviction. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
LIVN trades on Nasdaq (the company is based in United Kingdom). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $80. Entered 2026-08-04 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-04Markup$80.14+0.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $80.
2026-07-18Markup$79.39+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $80.
2026-07-03Markup$79.39+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$79.39Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$70.09
+11.9%
·
$1,119
+11.9%
2 months
$62.78
+24.9%
·
$1,249
+24.9%
3 months
$59.30
+32.2%
·
$1,322
+32.2%
6 months
$63.95
+22.6%
·
$1,226
+22.6%
1 year
$47.60
+64.7%
·
$1,647
+64.7%
2 years
$52.81
+48.5%
·
$1,485
+48.5%
3 years
$47.43
+65.3%
·
$1,653
+65.3%
5 years
$81.79
-4.1%
·
$959
-4.1%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever LIVN does next, these words stay.
LivaNova PLC · LIVN · Markup · $80.78
Recorded 2026-08-12 · before the outcome · scored mechanically
